Acrux Limited (ASX:ACR) has reported net sales of Axiron of $US36.3 million in the third quarter by its US licensee Eli Lilly.
The drug delivery company says sales by Lilly, of its key product Axiron, were sitting at $US122.9 million in the 9 months to the end of the third quarter.
The Axiron product is marketed in the US by Eli Lilly under a licensing deal that pays royalties to the company.
No royalties figures were included with the company’s sales report.
Acrux reported a net profit of $27.9 million in the first half of the 2014 financial year.